Table 1.
Clinical and demographic features of RA patients.
| Variable | RA DAS28 | p Value | ||||
|---|---|---|---|---|---|---|
| RA Total (n = 101) | Remission (n = 27) | Low (n = 16) |
Moderate (n = 35) | High (n = 23) |
||
| Demographics | ||||||
| Gender b | ||||||
| Female Male | 80.2 (81/101) 19.8 (20/101) |
59.3 (16/27) 40.7 (11/27) |
87.5 (14/16) 12.5 (2/16) |
85.7 (30/35) 14.3 (5/35) |
91.3 (21/23) 8.7 (2/23) |
- - |
| Age (years) c | 54 (19–91) | 52 (23–73) | 53.5 (40–91) | 54 (19–81) | 57 (22–88) | 0.681 |
| Disease status | ||||||
| DAS28 | 3.61 (0.97–7.5) | 2.17 (0.97–2.58) | 2.95 (2.63–3.17) | 4.13 (2.96–5.07) | 5.65 (5.17–7.56) | 0.000 |
| Disease evolution (years) c | 7 (0.6–40) | 4.5 (2–25) | 7 (1–23) | 9 (1–35) | 8 (1–40) | 0.237 |
| Clinical assessment Rheumatoid Factor (UI/mL) c Rheumatoid Factor Negative (<20 UI/mL) Positive (≥20 <60 UI/mL) High Positive (≥60 UI/mL) hsCRP (mg/L) c ESR (mm/h) c Spanish HAQ-D score c |
41.6 (42/101) - 32.9 (25/76) 67.1 (51/76) 6 (0.3–54.5) 37 (3–64) 0.62 (0–2.87) |
56 (34.26–89.58) - 50 (9/18) 50 (9/18) 2.1 (0.3–17.2) 18 (3–40) 0.125 (0–0.88) |
80.9 (70.34–88.27) - 20 (1/5) 80 (4/5) 7.3 (4.1–47.9) 31.5 (6–53) 0.5 (0–2.38) |
79.9 (38.8–89.8) - 33.3 (11/33) 66.7 (22/33) 5.3 (1.2–54.5) 43 (13–55) 0.75 (0–2.63) |
73.1 (36.7.24–87.5) - 20 (4/20) 80 (16/20) 10.2 (2.3–42.7) 43 (20–64) 1.4 (0.13–2.87) |
0.022 - - - 0.001 0.000 0.000 |
| Treatment b | ||||||
| NSAIDs | 41.6 (42/101) | 40.7 (11/27) | 56.3 (9/16) | 40 (14/35) | 34.8 (8/23) | - |
| Methotrexate | 80.2 (81/101) | 81.5 (22/27) | 81.3 (13/16) | 77.1 (27/35) | 82.6 (19/23) | - |
| Methotrexate (mg/week) c | 15 (0–60) | 15 (0–60) | 12.5 (0–15) | 15 (0–25) | 15 (0–25) | - |
| Sulfasalazine | 80.2 (81/101) | 85.2 (23/27) | 62.5 (10/16) | 77.1 (27/35) | 91.3 (21/23) | - |
| Sulfasalazine (mg/12 h) c | 500 (0–3000) | 500 (0–1000) | 375 (0–2000) | 500 (0–3000) | 500 (0–3000) | - |
| Antimalarial | 31.7 (32/101) | 40.7 (11/27) | 37.5 (6/16) | 31.4 (11/35) | 17.4 (4/23) | - |
| Antimalarial (mg/12 h) c | 0 (0–100) | 0 (0–100) | 0 (0–75) | 0 (0–100) | 0 (0–75) | - |
| No treatment | 3 (3/101) | 3.7 (1/27) | 0 (0/16) | 2.9 (1/35) | 4.3 (1/23) | - |
b Data in percentage (n), c Median data (range), NSAIDs: non-steroidal anti-inflammatory drugs, DAS28: Disease Activity Score 28. HAQ-Di: Health assessment questionnaire disability index, hsCRP: high sensibility C Reactive Protein, ESR: erythrocyte sedimentation rate, RA: rheumatoid arthritis, CS: control subject.